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Abstract 
The adaptor protein 3BP2 (c-Abl Src homology 3 domain-binding protein-2, also referred 
to SH3BP2) is known to play a regulatory role in signaling from immunoreceptors.  In 
mast cells, 3BP2 is rapidly tyrosine phosphorylated by the aggregation of the high 
affinity IgE receptor and the overexpression of its SH2 domain results in the dramatic 
suppression of IgE-mediated tyrosine phosphorylation of PLC-γ, Ca2+ mobilization and 
degranulation.  3BP2 is a substrate of the protein-tyrosine kinase Syk, which 
phosphorylates it on Tyr174, Tyr183, and Tyr446 (in the mouse protein).  Phosphorylation of 
Tyr183 promotes the activation of Rac1 through the interaction with the SH2 domain of 
Vav1.  Phosphorylation of Tyr446 induces the binding to the SH2 domain of the upstream 
protein-tyrosine kinase Lyn and enhances its kinase activity.  Thus, 3BP2 has a positive 
regulatory role in IgE-mediated mast cell activation.  In lymphocytes, engagement of T 
cell or B cell receptors triggers tyrosine phosphorylation of 3BP2.  Suppression of the 
3BP2 expression by siRNA results in the inhibition of T cell or B cell receptor-mediated 
activation of NFAT.  Genetic analyses reveal that 3BP2 is required for the proliferation 
of B cells and B cell receptor signaling.  Point mutations of the 3BP2 gene cause the rare 
human inherited disorder cherubism, characterized by excessive bone resorption in the 
jaw bones.  These mutations include substitution and deletion mutations of 3BP2.  
“Cherubism” mice exhibit increased myeloid cell responses to M-CSF and RANKL 
leading to the activation of osteoclasts.  Further analysis could demonstrate that inhibition 
of 3BP2 might have therapeutic potential.  
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Introduction 
Molecular scaffold, also called adaptor proteins, have indispensable roles to link the 
receptor-activating signals to downstream effectors by assembling, targeting and 
regulating signaling molecules.  Several adaptor proteins are the substrates of proximal 
protein-tyrosine kinases (PTKs).  These molecules lack catalytic activity, but they have 
multiple motifs and domains that allow binding to other signaling molecules and 
therefore act as positive or negative regulators controlling intracellular signal 
transduction.   
 
In 1993, an adaptor protein 3BP2 and the related molecule 3BP1were isolated through 
their capacity to bind to the Src homology 3 (SH3) domain of the proto-oncogene product 
c-Abl in a cDNA expression library screen [1].  Short Pro-rich sequences of 3BP1 and 
3BP2 have been shown to mediate association with the c-Abl-SH3 domain.  In vitro 
binding experiments demonstrate that Pro-rich regions of 3BP2 preferentially binds to the 
SH3 domains of c-Abl, c-Src and GRB2, and poorly to those of Nck and neural Src, 
suggesting that there is specificity in the binding of 3BP2 Pro-rich regions for the 
different SH3 domains.  3BP1 and 3BP2 are not homologous molecules.  3BP1 contains 
GAP (GTPase activating proteins) homology domain in the central portion, whereas 
3BP2 possesses an SH2 domain at its carboxy terminal region [2,3] (Fig. 1).  In 1998, 
3BP2 was also isolated as one of the Syk-kinase interacting proteins by yeast two-hybrid 
screening [4]. 
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Cherubism is an autosomal dominant disease characterized by multiple symmetrical cysts 
in the mandible and maxilla, excessive bone degradation, and typical facial swelling.  
Genetic analyses identify several substitution and a deletion mutation in the 3BP2 gene 
on chromosome 4p16.3 (Table 1) [5-11].  Deletion of 4p16.3 also correlates with Wolf-
Hirschhorn syndrome and bladder cancer [12,13].  Here we review the structure and 
function of 3BP2, implications of 3BP2 mutations in the pathogenesis of cherubism, and 
the possible role of 3BP2 in intracellular signals of osteoimmune cells.   
 
I. Structure of 3BP2 
The 3BP2 protein is composed of a PH (pleckstrin homology) domain, Pro-rich regions, a 
cherubism region, and an SH2 domain (Fig. 1).  The PH domain is required for the 
interaction with phosphatidylinositol 3,4,5-triphosphate which recruits 3BP2 to the 
plasma membrane for interactions with other signaling molecules.  Thus deletion of the 
PH domain causes the dysfunction of 3BP2 in T and B lymphocytes [4,14].  
 
The  Pro-rich regions (PR1, PR2, and PR3) of 3BP2 are known to associate with the SH3 
domain of c-Abl, Src family PTKs (Fyn, Lyn, and Lck), Vav family of guanine 
nucleotide exchanging factors, CIN85 (Cbl interacting protein of 85 kDa, also referred as 
CD2AP/SH3KBP1), and HIP-55 (hematopoietic progenitor kinase 1 interacting protein 
of 55 kDa, also referred as SH3P7/mAbp1) [1,4,14-17].  Domain-deletion studies 
demonstrate that PR1 is critical for the interaction with Vav1, Vav2, and CIN85 [14,17].  
The binding region of CIN85-SH3 domains on 3BP2 is mapped to the Pro-Val-Pro-Thr-
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Pro-Arg motif in PR1.  On the other hand, PR3 is required for 3BP2 interaction with HIP-
55 [17].  PR2 is not involved in the interaction with those molecules. 
 
The SH2 domain of 3BP2 interacts with Syk family PTKs, Syk and ZAP-70 [4].  This 
interaction of 3BP2 with Syk requires the SH2 domain of 3BP2 and the kinase activity of 
Syk, suggesting that 3BP2-SH2 domain associates with autophosphorylated Tyr 
residue(s) in the linker or kinase domain of Syk [4].  The SH2 domain has also been 
shown to interact with various signaling molecules in different cells.  In vitro binding 
studies demonstrate that TCR (T cell receptor) stimulation results in the binding of 3BP2 
by its SH2 domain to ZAP-70, LAT, Grb2, PLC (phospholipase C)-γ1, and c-Cbl [4].   
 
In 1994, the specific motifs recognized by the SH2 domain of 3BP2 was analyzed by 
using a degenerate peptide library [18].  The SH2 domain of 3BP2 has a strong 
preference for Glu at +1 and Asn at +2 positions after pTyr.  Therefore, 3BP2-SH2 
domain is thought to bind to the Tyr-Glu-Asn motif.  An adaptor protein LAT has two 
copies of this motif (Tyr120 and Tyr226).  In fact, 3BP2-SH2 domain associates with LAT 
after the stimulation of the high affinity IgE receptor (FcεRI) in mast cells [19].  In NK 
cells, CD244 (also named 2B4) also has the similar sequence (Tyr-Glu-Val) in the 
cytoplasmic tail within the ITSM (immunoreceptor tyrosine-based switch motif).  CD244 
is a member of the SLAM (signaling lymphocyte activation molecules) related  receptors 
that are expressed on NK and cytotoxic T cells [20].  Tyr337 in this sequence is 
phosphorylated by cross-linking of CD244, and this phosphorylation of Tyr337 allows 
binding to the 3BP2-SH2 domain [21].  B cell CD19 possesses four copies of the Tyr-
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Glu-Asn motif and two of them (Tyr403 and Tyr443) interact with the SH2 domain of 3BP2 
[22].  Furthermore, the protein-tyrosine phosphatase SHP-1 in pervanadate-treated 293T 
cells binds to the 3BP2-SH2 domain following phosphorylation of Tyr566 in SHP-1 by 
Lck [23].   
 
3BP2 is tyrosine phosphorylated when it is coexpressed with Syk and Src family PTKs 
[15,19,24].  Syk phosphorylates 3BP2 on Tyr174, Tyr183, and Tyr446 (in the mouse protein) 
(Fig. 2) [15].  Since Tyr183 of 3BP2 is part of the consensus binding sequence for the SH2 
domain of Vav1 (Tyr-Leu-Glu-Pro), phosphorylation of Tyr183 of 3BP2 may create an 
interaction site for Vav1-SH2 domain.  In vitro binding experiments show that a 
synthesized peptide encompassing phospho-Tyr183 of 3BP2 binds to Vav-1, PLC-γ1 and 
PLC-γ2 from pervanadate-stimulated human NK cells [24].  However, the biological 
relevance of these bindings remain unclear because treatment of cells with pervanadate, a 
non-specific inhibitor of protein-tyrosine phosphatase, strongly increases tyrosine 
phosphorylation of cellular proteins.  In mast cells, a point mutation of Tyr183 to Phe 
abrogates the association of 3BP2 with Vav1-SH2 domain (Fig. 2) [25].   
 
Tyr174 and Tyr446 which are located in the Asp-Tyr-Glu motif, match predicted Syk-
substrate sequences as determined by phage display experiments (Fig. 2) [26].  
Phosphorylation of Tyr446 creates the binding site for the SH2 domain of Lyn in mast 
cells and Lck in T cells (Fig. 2) [15,16].  Although 3BP2 is a substrate of Syk, 
phosphorylation of Tyr446 in 3BP2 increases phosphorylation of Syk by the activation of 
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the upstream Src family kinase Lyn, suggesting that 3BP2 is an activator of Syk (Fig. 2) 
[15].  The role of phosphorylation of Tyr174 in 3BP2 is still unclear.  
 
Ser225 and Ser277 in 3BP2 are the putative phosphorylation sites by cAMP-dependent 
protein kinase, protein kinase C, or Akt [27].  Phosphorylation of 3BP2 by serine kinases 
causes the interaction with the scaffold protein 14-3-3;  a point mutation of Ser277 
abrogates this interaction with 14-3-3 and elevates 3BP2-mediated NFAT (nuclear factor 
of activated T cells) activity in T cells and B cells.  In mast cells, expression of 3BP2 
with a point mutation of Ser277 increases IgE-mediated degranulation (Fig. 2) [25].  These 
findings suggest that Ser277 plays a negative regulatory role in 3BP2-mediated cell 
function.  
 
Genetic studies of patients with cherubism have identified mutation in 3BP2 including 
eleven substitutions and one deletion (Table 1).  All of these substitution mutations cause 
change of amino acids located within a limited sequence of 3BP2 (hot spot region of 
cherubism: Arg415-Ser-Pro-Pro-Asp-Gly420) (in the human protein) (Fig. 1).  Within this 
sequence, substitutions on Ser416 and Pro417 have not yet been reported.  Recently an 
aggressive case of cherubism was reported with a deletion mutation in 3BP2 (Table 1) 
[11].  This mutation corresponds to a deletion of cytosine that causes a silent mutation in 
Arg49 (CGC to CG/T) and leads to frame-shift mutations (50 to 74 a.a.) followed by a 
stop codon (TGA) within the PH domain of 3BP2, with the loss of the Pro-rich regions 
and the SH2 domain.  Thus, this deletion mutation causes the loss of 3BP2 expression.  
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Histological feature of giant cell granuloma of the jaw is similar to that of cherubism, but 
3BP2 is normal. Detection of 3BP2 mutations can be useful in the deferential diagnosis 
of these conditions [28,29].  
 
II. Physiological Function of 3BP2 
In human tissues, 3BP2 mRNA has been detected in spleen, peripheral blood leukocytes, 
and to a lesser extent in the thymus [4] while PCR screening additionally detects  mRNA 
in the testis and ovary [4].  Moreover, 3BP2 transcripts are observed in primary 
osteoblasts and cultured osteoclasts [5].  Gene chip analysis shows that 3BP2 mRNA is 
expressed in bone, oocytes, lungs, and lymph nodes in normal mouse tissues, with 
especially high expression in B lymphocytes [22].  In cultured cell lines 3BP2 protein is 
expressed in hematopoietic lineage cells, epithelial cells, fibroblasts, and glioma cells 
(Table 2).  In preliminary experiments we observed 3BP2 expression in the mouse 
osteoblastic MC3T3-E1 cell line and the mouse macrophage RAW264.7 cells, 
progenitors of osteoclasts (Hatani and Sada, unpublished observations).   
 
T cells 
Engagement of the TCR induces the sequential activation of the nonreceptor type PTKs 
Lck and ZAP-70 which amplify the receptor initiated signals.  Deckert et al. was the first 
to show the adaptive function of 3BP2 in T cells, which had been described previously as 
a c-Abl SH3-interacting protein of unknown function [4].  In these cells, the 
overexpression of 3BP2 induces the transcriptional activation of NFAT, AP-1, and IL-2 
(interleukin-2) promoter [4].  In T cells, receptor stimulation results in 3BP2 
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phosphorylation on both serine and tyrosine residues [16,23]; phosphorylation of Ser277 is 
required for the interaction with scaffold protein 14-3-3, and this interaction negatively 
regulates the 3BP2-mediated NFAT activation [27].  Phosphorylation of Tyr183 and Tyr446 
(in the mouse protein), as well as the SH2 domain of 3BP2 contributes to TCR-mediated 
activation of NFAT [16]. The decreased expression of 3BP2 with siRNA (short 
interfering RNA) blocks TCR-mediated activation of the IL-2 promoter and NFAT [16].  
These findings demonstrate that 3BP2 has a regulatory function in T cell signaling. 
 
Some 3BP2 translocates to the lipid raft (glycolipid-enriched microdomains: GEMs) in 
the plasma membrane after receptor stimulation [16,17] with 3BP2 co-localization with 
CIN85 and HIP-55 at the immunological synapse, T cell-APC interface [17].  Interaction 
of 3BP2 with these molecules suggests a role for 3BP2 in endocytosis and cytoskeletal 
rearrangements.   
 
Although 3BP2 is a positive regulator of TCR signaling, the possible abnormality of T 
cell signaling by the point mutation of 3BP2 does not affect the phenotype of the mouse 
model of cherubism [30].   
 
B cells 
Analysis of the tissue distribution of 3BP2 reveals the predominant expression of 3BP2 
mRNA in B cells [4].  3BP2 is tyrosine phosphorylated following BCR (B cell receptor) 
aggregation [14] and couples proximal PTKs and Vav family proteins to activate Rho 
family GTPases.  Decreased expression of 3BP2 by siRNA blocks BCR-mediated 
10 
activation of NFAT suggesting that 3BP2 is required for BCR coupling to NFAT 
activation [14].  In 3BP2-deficient mice there is normal T cell development, proliferation, 
cytokine secretion, and signaling in response to TCR ligation [31].  Although there is 
increased accumulation of pre-B cells in the bone marrow, there are normal numbers of 
mature B cells in 3BP2-/- mice.  However, B cell proliferation, cell cycle progression, and 
signaling in response to BCR ligation are all impaired.  Another study observed 
perturbation in the peritoneal B1 and splenic marginal-zone B cell compartments and 
diminish thymus-independent type 2 antigen response in 3BP2-/- mice [22].  These 
findings suggest that 3BP2 is critical for BCR, but not for TCR signaling.  T cells could 
still have a homologous molecule which has a redundant function of 3BP2.   
  
NK cells 
Cross-linking of FcγR induces tyrosine phosphorylation of 3BP2 in NK cells [24] and  
overexpression of this protein in NK cells results in the stimulation of FcγR-mediated 
cytotoxicity.  Both the PH and SH2 domains of 3BP2 are required for its tyrosine 
phosphorylation and 3BP2-mediated NK cell function.  Phosphorylation of Tyr183 in 
3BP2 causes its interaction with Vav and PLC-γ, and is necessary for the role of 3BP2 in 
cytotoxicity.  3BP2 also interacts with human, but not murine, CD244 in NK cells [21];  
CD244 is a member of the CD150 family and possesses ITSMs in the cytoplasmic region.  
CD244 ligation causes tyrosine phosphorylation of 3BP2 and recruitment of Vav1 to 
3BP2.  Overexpression of 3BP2 increases CD244-mediated cytotoxicity, but not IFN-γ 
secretion.  These findings demonstrated that 3BP2 plays a regulatory role on NK cell-
mediated cytotoxicity.   
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Mast cells 
Aggregation of the FcεRI induces mast cell activation leading to the release of histamine 
and production of cytokines.  In rat basophilic leukemia RBL-2H3 cells, FcεRI 
aggregation results in rapid 3BP2 tyrosine phosphorylation (Fig. 2) [19].  
Phosphorylation of Tyr446 contributes to the activation of Lyn suggesting that 3BP2 might 
be one of the factors regulating Lyn in FcεRI signaling (Fig. 2) [15].  Phosphorylation of 
Tyr183 creates the binding sites for Vav1-SH2 domain which regulates the activation of 
Rac1 (Fig. 2) [25].  Overexpression of mutant forms of 3BP2 provides insights to the 
function of endogenous molecule.  The FcεRI-mediated activation of IKK, JNK, ERK, 
NFAT, and cytokine production are all attenuated by the overexpression of the cherubism 
3BP2 mutants.  Overexpression of 3BP2-SH2 domain results in a suppression of FcεRI-
mediated tyrosine phosphorylation of PLC-γ, Ca2+ mobilization and degranulation (Fig. 
2) [19].  Expression of 3BP2 with a point mutation of Ser277 to Ala results in the 
enhancement of degranulation, cytokine production, and cellular signaling (Fig. 2) [25].  
Thus, phosphorylation of Ser277 may be involved in the negative regulation of mast cell 
function through the interaction with 14-3-3.  Altogether these observations demonstrate 
that 3BP2 regulates IgE-mediated cytokine production and degranulation.   
 
III. Implications of 3BP2 mutations in the pathogenesis of cherubism 
The studies summarized in the previous sections indicated the physiological function of 
3BP2 in lymphocytes and mast cells.  To understand the pathological role of 3BP2 in 
cherubism, Ueki et al introduced the most common mutation found in cherubism patients, 
12 
Pro416 to Arg (Pro418 to Arg in humans) into the mouse 3BP2 gene [30].  The homozygote 
of these “cherubism” mice (3BP2KI/KI) exhibits trabecular bone loss, enhanced osteoclast 
differentiation in tissues, TNF-α-dependent systemic inflammation, and cortical bone 
erosion.  Mutant myeloid cells show increased responses to M-CSF (macrophage-colony-
stimulating factor) and RANKL (RANK (receptor activation of NF-κB) ligand) 
stimulation, and differentiate to macrophages expressing high levels of TNF-α and 
unusually large osteoclasts.   
 
The systemic inflammation observed in cherubism mice is not improved by crossing 
these mice with RAG1-deficient mice (homozygous for the 3BP2 mutant allele and null 
for Rag1) which lack T and B cells, but the phenotype is rescued by crossing with TNF-
α-null mice [30].  Therefore although 3BP2 is a positive regulator of TCR and BCR 
signaling, mutation of 3BP2 in lymphocytes, T and B cells, was not the basis of the 
phenotype of cherubism mice.  Moreover, the absence of TNF-α rescues trabecular bone 
loss, but not enhanced osteoclastogenesis in response to M-CSF and RANKL in 
cherubism mice [30].  This indicates that in cherubism mice TNF-α-mediated bone loss 
and stimulated osteoclastogenesis are regulated by different mechanisms in macrophages 
and osteoclasts.   
 
Expression of the mutant form of 3BP2 causes sustained ERK phosphorylation in 
macrophages and increased Syk Tyr346 phosphorylation in osteoclasts.  Phosphorylation 
of Tyr346 in Syk (in the mouse protein) is elevated in 3BP2KI/KI mutant osteoclasts [30].  
Overexpression of the wild type and cherubism mutant form of 3BP2 increases M-CSF 
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and RANKL-mediated phosphorylation of Tyr346 in Syk, whereas phosphorylation of 
Tyr317 or Tyr519/Tyr520 (in the mouse protein) is not affected by the cherubism mutation of 
3BP2.  The mechanism by which the linker region Tyr residues (Tyr317, Tyr342, and 
Tyr346) in Syk are phosphorylated in the process of osteoclastogenesis remains unclear.  
Perhaps a member of the Src family PTKs or Syk itself phosphorylates Tyr346 [30].  The 
kinase activity of Syk is not affected by the cherubism mutation of 3BP2 because 
phosphorylation of Tyr519/Tyr520 in the activation loop of the kinase domain, which 
correlates with the kinase activity, is normal.  Altogether the observations of Ueki et al 
demonstrate that cherubism is a TNF-α dependent hematopoietic disorder [30].   
 
VI. Perspectives: Roles of 3BP2 in osteoimmune signals 
Cherubism results from the imbalance between the function of osteoblasts and osteoclasts 
in the jaw bone, both of which expresses 3BP2 [5].  The protein-tyrosine kinase Syk, 
several immunoreceptor tyrosine-based activation motif (ITAM)-bearing receptors or 
αvβ3 integrin have essential roles in the development of osteoclasts and activation of 
NFATc1 [32-34].  In addition, one of the Vav family proteins, Vav3, has a critical role in 
the regulation of osteoclasts [35].  Since 3BP2 is a substrate of Syk and regulates the 
activation of Vav family proteins in immune cells, it is likely that 3BP2 plays an 
important role in osteoimmune signals in osteoclasts (Fig. 3).  We previously 
demonstrated that overexpression of 3BP2 has a potential to affect the activation of IKK, 
JNK, and ERK [25].  Therefore, it is possible that dysfunction of 3BP2 affects the 
activation of those kinases in osteoclasts (Fig. 3).   
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Abl-deficient mice are osteoporotic and have defects in osteoblast maturation suggesting 
that Abl has an essential role in the development of osteoblasts, cells which also express 
3BP2 [5,36].  Since 3BP2 is a binding molecule of c-Abl, the cherubism mutation of 
3BP2 could affect the normal development and function of osteoblasts.   
 
Because cherubism is a rare disease affecting only a limited number of patients, it is 
unclear whether these patients have immunological defects. A recent report of an 
aggressive case who died of septicemia suggests an immunocompromised state [11].  
However, this case was due to a deletion mutation that resulted in the lack of the 
expression of full-length 3BP2.  Although in vitro 3BP2 is a positive regulator of 
lymphocytes, the phenotype in cherubism mice was not affected by the lack of T and B 
cells [30].  Thus, the phenotype in cherubism mice is not dependent on 3BP2 function in 
lymphocytes. Therefore, further analysis with selective inhibition of 3BP2 might have 
therapeutic potential.   
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Footnotes 
The abbreviations used are: PTKs, protein-tyrosine kinases; SH, Src homology; PH, 
pleckstrin homology; CIN85, Cbl interacting protein of 85 kDa; HIP-55 (hematopoietic 
progenitor kinase 1 interacting protein of 55 kDa; TCR, T cell receptor; LAT; linker for 
activation of T cells; PLC, phospholipase C; FcεRI, high affinity IgE receptor; ITSM, 
immunoreceptor tyrosine-based switch motif; NFAT, nuclear factor of activated T cells; 
IL-2, interleukin-2; siRNA, short interfering RNA; BCR, B cell receptor; M-CSF, 
macrophage-colony-stimulating factor; RANKL, RANK (receptor activation of NF-κB) 
ligand; ITAM, immunoreceptor tyrosine-based activation motif; CN, calcineurin. 
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Table 1 
Mutations of 3BP2 in cherubism 
Wild type   Mutant    References    
Substitutions 
Arg415 (CGA)   Pro (CCA)   [5] 
    Gln (CAA)   [5] 
Pro418 (CCC)   Leu (CTC)   [5] 
    Arg (CGC)   [5,7,30] 
    His (CAC)   [5] 
    Thr (ACC)   [10] 
Asp419 (GAT)   Asn (AAT)   [8] 
Gly (GGT)   [9] 
Gly420 (GGG)   Glu (GAG)   [5] 
   Arg (CGG)   [5] 
   Arg (AGG)   [6] 
Deletion 
Arg49 (CGC)   Arg (CG/T)   [11] 
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Table 2 
Cultured cell lines expressing 3BP2 
Cells        References 
T cells   Human Jurkat   [4,16,24] 
     CEM   [4] 
     HUT-78  [4] 
     KT-8   [24] 
   Mouse  DBHy3  [4]   
     B3Z   [4] 
B cells   Human Raji   [4,14,24] 
     C1R   [24] 
     CRL   [24] 
     BJAB   [14] 
     RPMI8866  [14] 
     Daudi   [14] 
NK cells  Human  YT   [21] 
Mast cells  Rat   RBL-2H3  [19,25] 
Monocytes  Human U937   [4,24] 
Myeloid cells  Human K562   [24] 
Epithelial cells Human  HeLa   [24] 
Fibroblasts  Human  GM847  [24] 
Glioma cells  Human Mo59K  [24] 
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Figure Legends 
Fig.  1 Structure of 3BP2. 
3BP2 is composed of a PH domain, Pro-rich regions (PR1-3), and an SH2 domain.  Both 
human and mouse a.a. numbers are shown.  Positions of point mutations are shown at the 
bottom.  
 
Fig.  2 Role of 3BP2 in mast cells.   
3BP2 plays regulatory roles in IgE-mediated mast cell activation.   
 
Fig.  3 Possible role of 3BP2 in osteoimmune signaling.  Dysfunction of 3BP2 in  
cherubism may affect the signaling pathways leading to the activation of NFATc1 in 
osteoclasts.  M-CSFR: M-CSF receptor.  Ig-like receptor: immunoglobulin-like receptor.  
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Fig. 1.  Hatani and Sada 
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Fig. 2.  Hatani and Sada
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Fig. 3.  Hatani and Sada 
